ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 232 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2021. The put-call ratio across all filers is 8.37 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,669,438 | -22.9% | 130,980 | -0.2% | 0.00% | 0.0% |
| Q2 2023 | $6,055,346 | -43.2% | 131,267 | -50.6% | 0.00% | -50.0% |
| Q1 2023 | $10,659,983 | -7.6% | 265,835 | +6.8% | 0.01% | -11.1% |
| Q4 2022 | $11,532,696 | +108.8% | 248,925 | +86.6% | 0.01% | +125.0% |
| Q3 2022 | $5,524,000 | +9.6% | 133,384 | +57.9% | 0.00% | 0.0% |
| Q2 2022 | $5,039,000 | +196.8% | 84,466 | +261.2% | 0.00% | +300.0% |
| Q1 2022 | $1,698,000 | -65.7% | 23,383 | -60.3% | 0.00% | -66.7% |
| Q4 2021 | $4,957,000 | +84.8% | 58,948 | +98.2% | 0.00% | +50.0% |
| Q3 2021 | $2,683,000 | -49.0% | 29,749 | -46.1% | 0.00% | -33.3% |
| Q2 2021 | $5,259,000 | -3.8% | 55,165 | +14.9% | 0.00% | -25.0% |
| Q1 2021 | $5,469,000 | -5.9% | 48,028 | +14.4% | 0.00% | +33.3% |
| Q4 2020 | $5,810,000 | +1071.4% | 41,967 | +594.8% | 0.00% | – |
| Q3 2020 | $496,000 | -83.0% | 6,040 | -83.8% | 0.00% | -100.0% |
| Q2 2020 | $2,923,000 | +16.2% | 37,374 | -34.0% | 0.00% | 0.0% |
| Q1 2020 | $2,516,000 | +76.1% | 56,642 | +69.4% | 0.00% | +100.0% |
| Q4 2019 | $1,429,000 | -51.2% | 33,441 | -51.2% | 0.00% | -50.0% |
| Q3 2019 | $2,930,000 | +12.1% | 68,500 | +66.5% | 0.00% | 0.0% |
| Q2 2019 | $2,613,000 | -1.6% | 41,135 | +7.5% | 0.00% | -33.3% |
| Q1 2019 | $2,656,000 | -52.5% | 38,277 | -70.2% | 0.00% | -50.0% |
| Q4 2018 | $5,587,000 | -41.5% | 128,481 | +2.7% | 0.01% | -25.0% |
| Q3 2018 | $9,552,000 | +737.2% | 125,111 | +741.8% | 0.01% | +700.0% |
| Q2 2018 | $1,141,000 | -43.8% | 14,862 | -62.7% | 0.00% | -50.0% |
| Q1 2018 | $2,032,000 | -9.1% | 39,879 | -17.3% | 0.00% | 0.0% |
| Q4 2017 | $2,236,000 | +48.8% | 48,219 | +70.9% | 0.00% | +100.0% |
| Q3 2017 | $1,503,000 | -42.1% | 28,216 | -32.5% | 0.00% | -50.0% |
| Q2 2017 | $2,594,000 | -15.5% | 41,774 | -7.8% | 0.00% | -33.3% |
| Q1 2017 | $3,069,000 | -70.2% | 45,296 | -69.1% | 0.00% | -66.7% |
| Q4 2016 | $10,310,000 | +850.2% | 146,644 | +859.1% | 0.01% | +800.0% |
| Q3 2016 | $1,085,000 | +148.3% | 15,290 | +71.1% | 0.00% | – |
| Q2 2016 | $437,000 | -81.3% | 8,935 | -75.8% | 0.00% | -100.0% |
| Q1 2016 | $2,335,000 | +68.8% | 36,885 | +199.1% | 0.00% | +200.0% |
| Q4 2015 | $1,383,000 | +561.7% | 12,331 | +468.8% | 0.00% | – |
| Q3 2015 | $209,000 | -30.6% | 2,168 | -26.5% | 0.00% | – |
| Q2 2015 | $301,000 | -40.5% | 2,948 | -63.8% | 0.00% | – |
| Q1 2015 | $506,000 | +25.6% | 8,151 | -11.2% | 0.00% | – |
| Q4 2014 | $403,000 | +722.4% | 9,176 | +954.7% | 0.00% | – |
| Q3 2014 | $49,000 | +250.0% | 870 | +167.7% | 0.00% | – |
| Q2 2014 | $14,000 | +1300.0% | 325 | +1254.2% | 0.00% | – |
| Q1 2014 | $1,000 | – | 24 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |